Hospital
Baldwin Area Medical Center, INC.
Baldwin Area Medical Center, INC. was paid $3.09M by Medicaid between Jan 2018 and Dec 2024, across 92 billing codes. Its largest line is 99282, Emergency department visit for the evaluation and management, low to moderate severity — 24% of everything it billed.
33Billing provider infoBALDWIN AREA MEDICAL CENTER, INC.
BALDWIN, WI 54002
BALDWIN, WI 54002
33aNPI1467496133assigned 06/15/2006
33bProvider typeCritical Access Hospital
28Total paid$3.09M
24GClaims80,861
24DCodes billed92
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Wisconsin
Rank by total paid#30 of 48
Median peer was paid$4.30M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,911 | $304K | |
| 2019 | 8,592 | $307K | |
| 2020 | 8,243 | $321K | |
| 2021 | 11,792 | $445K | |
| 2022 | 14,300 | $565K | |
| 2023 | 15,490 | $629K | |
| 2024incomplete | 15,533 | $521K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 24% | 2,953 | 2,461 | $740K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 3,124 | 2,413 | $635K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 13% | 2,390 | 2,018 | $393K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.4% | 515 | 375 | $290K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 4.6% | 453 | 263 | $142K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.2% | 1,554 | 1,396 | $130K |
| 71046 | Radiologic examination, chest; 2 views | 2.6% | 1,556 | 1,355 | $79K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 7,603 | 5,756 | $68K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.8% | 623 | 497 | $56K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 1,394 | 1,258 | $47K |
| 80053 | Comprehensive metabolic panel | 1.5% | 4,133 | 3,324 | $46K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 112 | 98 | $38K |
80 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 118 | $38K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.0% | 901 | $32K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,373 | $30K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,561 | $30K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,266 | $26K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 266 | $25K |
| 87081 | <1% | 2,140 | $23K | |
| 80306 | <1% | 1,059 | $18K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 998 | $14K |
| 80061 | Lipid panel | <1% | 1,050 | $12K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,480 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,065 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,435 | $11K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 251 | $10K |
| 87400 | <1% | 516 | $10K | |
| 85610 | <1% | 1,615 | $10K | |
| G0127 | Trimming of dystrophic nails, any number | <1% | 150 | $8K |
| 81001 | <1% | 2,121 | $8K | |
| 84484 | <1% | 748 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 260 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 260 | $7K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 418 | $7K |
| 73630 | <1% | 86 | $6K | |
| 59025 | Fetal non-stress test | <1% | 18 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 385 | $6K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $6K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 163 | $5K |
| 81003 | <1% | 769 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,911 | $3K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 643 | $3K |
| 84439 | <1% | 401 | $3K | |
| 82728 | <1% | 281 | $3K | |
| 81025 | <1% | 364 | $2K | |
| G0400 | Home sleep test (hst) with type iv portable monitor, unattended; minimum of 3 channels | <1% | 12 | $2K |
| 86803 | <1% | 179 | $2K | |
| 83655 | <1% | 138 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 100 | $2K |
| 86780 | <1% | 174 | $2K | |
| 83690 | <1% | 370 | $1K | |
| 85018 | <1% | 515 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 131 | $1K |
| 87077 | <1% | 196 | $1K | |
| 82248 | <1% | 345 | $907.83 | |
| 85027 | <1% | 206 | $787.95 | |
| 36416 | <1% | 221 | $760.69 | |
| 87653 | <1% | 25 | $757.20 | |
| 87186 | <1% | 135 | $659.61 | |
| 86140 | <1% | 187 | $622.57 | |
| 83735 | <1% | 150 | $590.25 | |
| 86850 | <1% | 129 | $492.64 | |
| 83605 | <1% | 87 | $373.77 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 13 | $320.46 |
| 71045 | Radiologic examination, chest; single view | <1% | 149 | $268.91 |
| 87340 | <1% | 32 | $234.74 | |
| 86901 | <1% | 107 | $222.48 | |
| 87467 | <1% | 14 | $210.70 | |
| 86900 | <1% | 90 | $185.40 | |
| 87210 | <1% | 39 | $150.00 | |
| 82950 | <1% | 14 | $134.01 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 21 | $109.86 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 475 | $61.48 |
| 85652 | <1% | 39 | $50.22 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,150 | $45.53 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,907 | $10.77 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,257 | $8.10 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,373 | $5.01 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 418 | $4.37 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 634 | $2.01 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 995 | $1.54 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 442 | $0.56 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 362 | $0.49 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 22 | $0.37 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 341 | $0.06 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 243 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 94 | $0.00 |
| J3490 | Unclassified drugs | 0% | 545 | $0.00 |
| A9270 | Non-covered item or service | 0% | 128 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 89 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 41 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPEDERSON, EILIDH (CEO)
| Provider | Location | Paid |
|---|---|---|
| Baldwin Area Medical Center, INC. | Baldwin, WI | $1.36M |
| Baldwin Area Medical Center, INC. | Roberts, WI | $34K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.